Subject : A survey to understand the treatment landscape in management of bipolar depression and place of Lumateperone in bipolar depression therapy
The global prevalence of bipolar disorder is approximately 2%. Data from the latest World Mental Health surveys between 2001 and 2022 involving 156,331 respondents across 29 countries reported a lifetime prevalence of 2.5% (95% CI, 2.4%-2.7%) in men and 2.3% (95% CI, 2.1%- 2.4%) in women. In 2016, the National Mental Health Survey was published and the lifetime prevalence of bipolar disorders in their sample was 0.5%, whereas the current prevalence was estimated at 0.3%. Another study evaluated the sociodemographic and clinical profiles of patients with bipolar disorder receiving ECT (n = 178) during the period 2016–2020, and it was found that 63.5% had bipolar depression and the rest had mania or mixed episode; the majority showed clinical response with a very few patients developing complications.
When compared with mania, there are few medications with proven efficacy in the treatment of acute bipolar depression, particularly bipolar II depression. Quetiapine monotherapy, olanzapine in combination with fluoxetine, and (most recently) lurasidone monotherapy or in combination with lithium or valproate are the sole US Food and Drug Administration (FDA)–approved medications for bipolar I depression, while only quetiapine is approved for bipolar II depression. Lamotrigine showed a small but significant improvement in depressive symptoms compared with placebo in a pooled analysis of 5 acute randomized controlled trials, but 4 of these 5 studies were underpowered and failed to show a superiority of lamotrigine over placebo. Despite fact that BD II is as prevalent as BD I, and that patients with BD II have comparable rates of comorbidity, chronicity, disability, and suicidality, only quetiapine and Lumateperone are approved for acute treatment of depression in patients with BD II. Quetiapine is NOT approved for Bipolar depression in India; only lumateperone approved for bipolar depression in India
Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin 5-HT2A receptors and central dopamine D2 receptors. The dual actions of lumateperone, increasing phosphorylation at NMDA receptors to enhance glutamate signaling and inhibiting SERT to augment serotonin levels, highlight its unique pharmacological profile.
This survey has been undertaken to understand the treatment landscape in management of bipolar depression and place of Lumateperone in bipolar depression therapy.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})